Cargando…
No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536703/ https://www.ncbi.nlm.nih.gov/pubmed/37759276 http://dx.doi.org/10.1186/s42466-023-00277-1 |
_version_ | 1785112933743722496 |
---|---|
author | de Boni, Laura Odainic, Alexandru Gancarczyk, Natalie Kaluza, Luisa Strassburg, Christian P. Kersting, Xenia A. K. Wüllner, Ullrich Schmidt, Susanne V. Petzold, Gabor C. |
author_facet | de Boni, Laura Odainic, Alexandru Gancarczyk, Natalie Kaluza, Luisa Strassburg, Christian P. Kersting, Xenia A. K. Wüllner, Ullrich Schmidt, Susanne V. Petzold, Gabor C. |
author_sort | de Boni, Laura |
collection | PubMed |
description | Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00277-1. |
format | Online Article Text |
id | pubmed-10536703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105367032023-09-29 No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache de Boni, Laura Odainic, Alexandru Gancarczyk, Natalie Kaluza, Luisa Strassburg, Christian P. Kersting, Xenia A. K. Wüllner, Ullrich Schmidt, Susanne V. Petzold, Gabor C. Neurol Res Pract Letter to the Editor Headache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00277-1. BioMed Central 2023-09-28 /pmc/articles/PMC10536703/ /pubmed/37759276 http://dx.doi.org/10.1186/s42466-023-00277-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Letter to the Editor de Boni, Laura Odainic, Alexandru Gancarczyk, Natalie Kaluza, Luisa Strassburg, Christian P. Kersting, Xenia A. K. Wüllner, Ullrich Schmidt, Susanne V. Petzold, Gabor C. No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title_full | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title_fullStr | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title_full_unstemmed | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title_short | No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache |
title_sort | no evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of neuro-covid-19 patients with long-term persistent headache |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536703/ https://www.ncbi.nlm.nih.gov/pubmed/37759276 http://dx.doi.org/10.1186/s42466-023-00277-1 |
work_keys_str_mv | AT debonilaura noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT odainicalexandru noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT gancarczyknatalie noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT kaluzaluisa noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT strassburgchristianp noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT kerstingxeniaak noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT wullnerullrich noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT schmidtsusannev noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache AT petzoldgaborc noevidenceforneuronaldamageorastrocyticactivationincerebrospinalfluidofneurocovid19patientswithlongtermpersistentheadache |